Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014 (2014), Article ID 560962, 6 pages
http://dx.doi.org/10.1155/2014/560962
Research Article

Development and Characterization of Nanoparticles for the Delivery of Gemcitabine Hydrochloride

Department of Pharmaceutics, SD College Pharmacy, Barnala Punjab 148101, India

Received 31 August 2013; Accepted 27 November 2013; Published 27 January 2014

Academic Editors: K. Kalishwaralal and Z. Wang

Copyright © 2014 Rekha Khaira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. S. Michaud, “Epidemiology of pancreatic cancer,” Minerva Chirurgica, vol. 59, no. 2, pp. 99–111, 2004. View at Google Scholar · View at Scopus
  2. E. Mitry, B. Rachet, M. J. Quinn, N. Cooper, and M. P. Coleman, “Survival from cancer of the pancreas in England and Wales up to 2001,” The British Journal of Cancer, vol. 99, no. 1, pp. S21–S23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Ishikawa, H. Kamimura, A. Tsuchiya et al., “Clinical efficacy of intra-arterial pharmacokinetic chemotherapy with 5-fluorouracil, CDDP, gemcitabine, and angiotensin-II in patients with advanced pancreatic cancer,” Hepato-Gastroenterology, vol. 54, no. 80, pp. 2378–2382, 2007. View at Google Scholar · View at Scopus
  4. S. Rosewicz and B. Wiedenmann, “Pancreatic carcinoma,” The Lancet, vol. 349, no. 9050, pp. 485–489, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. S. E. Sanchez and J. G. Trevino, “Current adjuvant and targeted therapies for pancreatic adenocarcinoma,” Current Medicinal Chemistry, vol. 15, no. 17, pp. 1674–1683, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. L. H. Reddy and P. Couvreur, “Novel approaches to deliver gemcitabine to cancers,” Current Pharmaceutical Design, vol. 14, no. 11, pp. 1124–1137, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. R. P. Abratt, “Gemcitabine hydrochloride: combination of activity and tolerability (summary),” Anti-Cancer Drugs, vol. 6, no. 6, pp. 63–64, 1995. View at Publisher · View at Google Scholar · View at Scopus
  8. Eli Lilly and Company, Summary of Product Characteristics: Gemcitabine UK Prescribing Information, Eli Lilly and Company, Indianapolis, Ind, USA, 1997.
  9. M. L. Immordino, P. Brusa, F. Rocco, S. Arpicco, M. Ceruti, and L. Cattel, “Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs,” Journal of Controlled Release, vol. 100, no. 3, pp. 331–346, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Myhren, B. Borretzen, A. Dalen, and M. Sandvold, “Gemcitabine derivative,” WO patent 32762, 1998.
  11. G. Pasut, F. Canal, L. Dalla Via, S. Arpicco, F. M. Veronese, and O. Schiavon, “Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid,” Journal of Controlled Release, vol. 127, no. 3, pp. 239–248, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Niu, Y. C. Xu, H. Y. Xie, Z. Dai, and H. Q. Tang, “Expression of human insulin gene wrapped with chitosan nanoparticles in NIH3T3 cells and diabetic rats,” Acta Pharmacologica Sinica, vol. 29, no. 11, pp. 1342–1349, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. W. J. Deng, X. Q. Yang, Y. J. Liang et al., “FG020326-loaded nanoparticle with PEG and PDLLA improved pharmacodynamics of reversing multidrug resistance in vitro and in vivo,” Acta Pharmacologica Sinica, vol. 28, no. 6, pp. 913–920, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. K. J. Widder, P. A. Marino, R. M. Morris, D. P. Howard, G. A. Poore, and A. E. Senyei, “Selective targeting of magnetic albumin microspheres to the Yoshida sarcoma: ultrastructural evaluation of microsphere disposition,” European Journal of Cancer and Clinical Oncology, vol. 19, no. 1, pp. 141–147, 1983. View at Google Scholar · View at Scopus
  15. Pharmacopoeia of India, Ministry of Health and Family Welfare, vol. 11, Controller of Publication, New Delhi, India, 2007.
  16. K. A. Janes, M. P. Fresneau, A. Marazuela, A. Fabra, and M. J. Alonso, “Chitosan nanoparticles as delivery systems for doxorubicin,” Journal of Controlled Release, vol. 73, no. 2-3, pp. 255–267, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. E. F. Craparo, G. Pitarresi, M. L. Bondi, M. P. Casaletto, M. Licciardi, and G. Giammona, “A nanoparticulate drug-delivery system for rivastigmine: physico-chemical and in vitro biological characterization,” Macromolecular Bioscience, vol. 8, no. 3, pp. 247–259, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Keum, Y. Noh, J. Baek et al., “Practical preparation procedures for docetaxel-loaded nanoparticles using polylactic acid-co-glycolic acid,” International Journal of Nanomedicine, vol. 6, pp. 2225–2234, 2011. View at Google Scholar · View at Scopus
  19. W. Zhu, A. Yu, W. Wang, R. Dong, J. Wu, and G. Zhai, “Formulation design of microemulsion for dermal delivery of penciclovir,” International Journal of Pharmaceutics, vol. 360, no. 1-2, pp. 184–190, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Ankarao, V. Naik, and K. H. Rao, “Formulation and in vitro evaluation of oral sustained release nanoparticulate delivery system of carvedilol,” International Journal of Research in Pharmaceutical and Biomedical sciences, vol. 3, no. 2, pp. 925–928, 2012. View at Google Scholar
  21. R. Ramachandran and P. Shanmughavel, “Preparation and characterization of biopolymeric nanoparticles used in drug delivery,” Indian Journal of Biochemistry and Biophysics, vol. 47, no. 1, pp. 56–59, 2010. View at Google Scholar · View at Scopus
  22. S. Sangeetha, K. Deepika, B. Thrishala, C. H. Chaitanya, G. Harish, and N. Damodharan, “Formulation and in vitro evaluation of sodium alginate nanospheres containing ofloxacin,” International Journal of Applied Pharmaceutics, vol. 2, no. 4, pp. 1–3, 2010. View at Google Scholar
  23. S. Ramesh, R. Ranganayakulu, S. P. Reddy, and E. Tejaswi, “Formulation and in vitro evaluation of nanoparticles containing ciprofloxacin hydrochloride,” Journal of Innovative Trends in Pharmaceutical Sciences, vol. 1, no. 2, pp. 79–85, 2010. View at Google Scholar
  24. P. Dandagi, P. Patel, P. Patil, V. Mastiholimath, and A. Gadad, “Development and characterization of a particulate drug delivery system for etoposide,” Indian Journal of Novel Drug Delivery, vol. 3, no. 1, pp. 43–51, 2011. View at Google Scholar
  25. V. Vichai and K. Kirtikara, “Sulforhodamine B colorimetric assay for cytotoxicity screening,” Nature Protocols, vol. 1, no. 3, pp. 1112–1116, 2006. View at Publisher · View at Google Scholar · View at Scopus